Patents by Inventor Aaron Rigby

Aaron Rigby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydro-benzo[d]azepine derivatives as GPR120 modulators
    Patent number: 11220483
    Abstract: Novel tetrahydroisoquinoline and tetrahydrobenzazepine compounds of formula (I) capable of modulating the G-protein-coupled receptor GPR120, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as of diabetes, inflammation, obesity and metabolic diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: January 11, 2022
    Assignee: CALDAN THERAPEUTICS LTD
    Inventors: Jane Brown, Stephen Connolly, Steffen V. F. Hansen, Gavin Milne, Bharat Shimpukade, Don Smyth, Gerard Thomas, Trond Ulven, Matjaz Brvar, Aaron Rigby
  • TETRAHYDRO-BENZO[D]AZEPINE DERIVATIVES AS GPR120 MODULATORS
    Publication number: 20200317619
    Abstract: Novel tetrahydroisoquinoline and tetrahydrobenzazepine compounds of formula (I) capable of modulating the G-protein-coupled receptor GPR120, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as of diabetes, inflammation, obesity and metabolic diseases.
    Type: Application
    Filed: March 26, 2018
    Publication date: October 8, 2020
    Inventors: Jane BROWN, Stephen CONNOLLY, Steffen V.F. HANSEN, Gavin MILNE, Bharat SHIMPUKADE, Don SMYTH, Gerard THOMAS, Trond ULVEN, Matjaz BRVAR, Aaron RIGBY
  • Kinase inhibitors
    Patent number: 10435361
    Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 8, 2019
    Assignee: Topivert Pharma Limited
    Inventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Gareth William Harbottle, Vedran Hasimbegovic, Premji Meghani, Aaron Rigby, Colin Sambrook-Smith, Stephen Malcolm Thom
  • KINASE INHIBITORS
    Publication number: 20180044288
    Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 15, 2018
    Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Gareth William HARBOTTLE, Vedran HASIMBEGOVIC, Premji MEGHANI, Aaron RIGBY, Colin SAMBROOK-SMITH, Stephen Malcolm THOM
  • Urea derivatives useful as kinase inhibitors
    Patent number: 9890185
    Abstract: There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: February 13, 2018
    Assignees: Respivert Limited, Topivert Pharma Limited
    Inventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom, Thomas Matthew Baker, Gareth William Harbottle, Vedran Hasimbegovic, Aaron Rigby
  • UREA DERIVATIVES USEFUL AS KINASE INHIBITORS
    Publication number: 20160318958
    Abstract: There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 3, 2016
    Inventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom, Thomas Matthew Baker, Gareth William Harbottle, Vedran Hasimbegovic, Aaron Rigby
  • Kinase inhibitors
    Patent number: 9481648
    Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: November 1, 2016
    Assignees: Respivert Limited, Topivert Pharma Limited
    Inventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Gareth William Harbottle, Vedran Hasimbegovic, Premji Meghani, Aaron Rigby, Colin Sambrook-Smith, Stephen Malcolm Thom
  • KINASE INHIBITORS
    Publication number: 20140296208
    Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Application
    Filed: April 1, 2014
    Publication date: October 2, 2014
    Applicants: Topivert Pharma Limited, Respivert Limited
    Inventors: Thomas Matthew BAKER, Matthew Colin Thor FYFE, Gareth William HARBOTTLE, Vedran HASIMBEGOVIC, Premji MEGHANI, Aaron RIGBY, Colin SAMBROOK-SMITH, Stephen Malcolm THOM
  • Bi-aryl amide compounds as CRTh2 receptor modulators
    Patent number: 8507544
    Abstract: The present invention relates to (2S)-2-({3?-Chloro-4?-[(2,2-dimethylpyrrolidin-1-yl) carbonyl]-5-fluorobiphenyl-2-yl}oxy)propanoic acid and (2R)-2-({3?-chloro-4?-[(2,2-dimethylpyrrolidin-1-yl) carbonyl]-5-fluorobiphenyl-2-yl}oxy)propanoic acid of formula (I), and crystalline forms and pharmaceutically acceptable salts thereof useful as pharmaceuticals.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: August 13, 2013
    Assignee: Astrazeneca AB
    Inventors: Roger Victor Bonnert, Timothy Jon Luker, Anil Patel, Aaron Rigby
  • Piperidines as chemokine modulators (CCR)
    Patent number: 7956070
    Abstract: Compounds of formula (I): are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).
    Type: Grant
    Filed: January 31, 2005
    Date of Patent: June 7, 2011
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Peter Cage, Mark Furber, Elizabeth Kinchin, Christopher Luckhurst, Aaron Rigby
  • Novel Compounds 951
    Publication number: 20090012151
    Abstract: The present invention relates to amide compounds useful as pharmaceuticals for treating respiratory disorders such as asthma, rhinitis and COPD.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 8, 2009
    Inventors: Roger Victor Bonnert, Timothy Jon Luker, Anil Patel, Aaron Rigby
  • Chemical compounds
    Publication number: 20070179297
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: April 3, 2007
    Publication date: August 2, 2007
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
  • Chemical compounds
    Patent number: 7238811
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: May 13, 2003
    Date of Patent: July 3, 2007
    Assignee: AstraZeneca AB
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
  • Novel piperidines as chemokine modulators (ccr)
    Publication number: 20070054924
    Abstract: Compounds of formula (I): are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).
    Type: Application
    Filed: January 31, 2005
    Publication date: March 8, 2007
    Inventors: Lilian Alcaraz, Peter Cage, Mark Furber, Elizabeth Kinchin, Christopher Luckhurst, Aaron Rigby
  • Chemical compounds
    Patent number: 7179922
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: February 20, 2007
    Assignee: AstraZeneca AB
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
  • Chemical compounds
    Publication number: 20050171092
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: March 10, 2005
    Publication date: August 4, 2005
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
  • Bipiperidine compounds
    Patent number: 6903115
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: June 7, 2005
    Assignee: AstraZeneca AB
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
  • Chemical compounds
    Publication number: 20040014783
    Abstract: The present invention provides a compound of a formula (I): 1
    Type: Application
    Filed: May 13, 2003
    Publication date: January 22, 2004
    Applicant: AstraZeneca AB, a Sweden corporation
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
  • Chemical compounds
    Publication number: 20040006080
    Abstract: The present invention provides a compound of a formula (I): 1
    Type: Application
    Filed: January 13, 2003
    Publication date: January 8, 2004
    Applicant: AstraZeneca AB, a Sweden corporation
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
  • Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists
    Patent number: 6525070
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: February 25, 2003
    Assignee: AstraZeneca AB
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence